What are the advantages for drug developers to choose advanced dosage forms for new molecules in the development pipelines? Or, are advanced dosage forms more suitable for expanding product portfolio with the existing molecules? How can innovators select the most suitable technologies to create these dosage forms for oral delivery?

To answer these questions, FiercePharma and Catalent recently conducted a survey to understand the factors affecting innovators' decision to choose a dosage form. In this webinar, industry experts will present the survey results and share insights on how advanced dosage forms can address the patient and molecule needs.